Identification and characterization of a potent and selective inhibitor of human urate transporter 1

[1]  N. Malara,et al.  The treatment of hyperuricemia. , 2016, International journal of cardiology.

[2]  Xilin Yang,et al.  Associations between serum uric acid and the incidence of hypertension: a Chinese senior dynamic cohort study , 2016, Journal of Translational Medicine.

[3]  N. Schlesinger,et al.  New and Pipeline Drugs for Gout , 2016, Current Rheumatology Reports.

[4]  N. Horiba,et al.  Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[5]  Sheridan M. Hoy.  Lesinurad: First Global Approval , 2016, Drugs.

[6]  H. Xie,et al.  Folic acid reverses uric acid crystal-induced surface OAT1 internalization by inhibiting RhoA activity in uric acid nephropathy , 2016, Molecular medicine reports.

[7]  Jiong Lan,et al.  Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model. , 2016, Bioorganic & medicinal chemistry letters.

[8]  M. Cravets,et al.  Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol , 2016, Annals of the rheumatic diseases.

[9]  C. Mende.  Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy , 2015, Advances in Therapy.

[10]  R. Blantz,et al.  Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[11]  Xu Liu,et al.  Mangiferin Inhibits Renal Urate Reabsorption by Modulating Urate Transporters in Experimental Hyperuricemia. , 2015, Biological & pharmaceutical bulletin.

[12]  S. Kardia,et al.  Uric Acid: A Missing Link Between Hypertensive Pregnancy Disorders and Future Cardiovascular Disease? , 2015, Mayo Clinic proceedings.

[13]  J. Singh,et al.  Investigational drugs for hyperuricemia , 2015, Expert opinion on investigational drugs.

[14]  C. Storgard,et al.  Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males , 2015, Drug design, development and therapy.

[15]  C. Díaz-Torné,et al.  New medications in development for the treatment of hyperuricemia of gout , 2015, Current opinion in rheumatology.

[16]  J. Fitzgerald,et al.  Evolution of management of gout: a comparison of recent guidelines , 2015, Current opinion in rheumatology.

[17]  J. Ruan,et al.  Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice. , 2014, Journal of ethnopharmacology.

[18]  C. Peralta,et al.  Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  Shu-Qing Wang,et al.  Riparoside B and timosaponin J, two steroidal glycosides from Smilax riparia, resist to hyperuricemia based on URAT1 in hyperuricemic mice. , 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[20]  S. Zeng,et al.  Interaction of five anthraquinones from rhubarb with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8) and drug-drug interaction in rats. , 2014, Journal of ethnopharmacology.

[21]  M. Bach,et al.  Uricosuric drugs: the once and future therapy for hyperuricemia? , 2014, Current opinion in rheumatology.

[22]  L. Abenhaim,et al.  Impact of allopurinol on risk of myocardial infarction , 2014, Annals of the rheumatic diseases.

[23]  W. Welsh,et al.  Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization. , 2012, Molecular pharmaceutics.

[24]  G. Burckhardt.  Drug transport by Organic Anion Transporters (OATs). , 2012, Pharmacology & therapeutics.

[25]  Qing-Yu Zhang,et al.  Quercetin Protects against Cadmium-Induced Renal Uric Acid Transport System Alteration and Lipid Metabolism Disorder in Rats , 2012, Evidence-based complementary and alternative medicine : eCAM.

[26]  P. Sexton,et al.  Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.

[27]  C. H. Cheng,et al.  Morin (3,5,7,2′,4′-Pentahydroxyflavone) Exhibits Potent Inhibitory Actions on Urate Transport by the Human Urate Anion Transporter (hURAT1) Expressed in Human Embryonic Kidney Cells , 2007, Drug Metabolism and Disposition.

[28]  Hirotaka Matsuo,et al.  Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.

[29]  H. Endou,et al.  Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. , 2001, European journal of pharmacology.

[30]  Yuichi Sugiyama,et al.  Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.